Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 48

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Endocrine Disorder in Patients With Craniopharyngioma

Zhou, Zihao, Zhang, Sheng, Hu, Fangqi · 2021 · Frontiers in Neurology

Abstract

Craniopharyngioma is an intracranial congenital epithelial tumor growing along the pathway of the embryonic craniopharyngeal tube. The main clinical symptoms of patients with craniopharyngioma include high intracranial pressure, visual field defect, endocrine dysfunction, and hypothalamic dysfunction. At present, the preferred treatment remains the surgical treatment, but the recovery of endocrine and hypothalamic function following surgery is limited. In addition, endocrine disorders often emerge following surgery, which seriously reduces the quality of life of patients after operation. So far, research on craniopharyngioma focuses on ways to ameliorate endocrine dysfunction. This article reviews the latest research progress on pathogenesis, manifestation, significance, and treatment of endocrine disorders in patients with craniopharyngioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2021.737743

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 112

  1. Fernandez-Miranda, 2012, Craniopharyngioma: a pathologic, clinical, and surgical review, Head Neck., 34, 1036, 10.1002/hed.21771 · DOI · Paper page
  2. Huang, 2021, Clinical and endocrinological manifestations of childhood-onset craniopharyngioma before surgical removal: a report from one medical center in Taiwan, Pediatr Neonatol., 62, 181, 10.1016/j.pedneo.2020.08.014 · DOI
  3. DeVile, 1996, Growth and endocrine sequelae of craniopharyngioma, Arch Dis Child., 75, 108, 10.1136/adc.75.2.108 · DOI · Paper page
  4. Jazbinsek, 2020, Prevalence of endocrine and metabolic comorbidities in a national cohort of patients with craniopharyngioma, Horm Res Paediatr., 93, 46, 10.1159/000507702 · DOI
  5. Wijnen, 2018, The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up, Eur J Endocrinol., 178, 11, 10.1530/EJE-17-0387 · DOI
  6. Hussein, 2020, Temporal trends in craniopharyngioma management and long-term endocrine outcomes: A multicentre cross-sectional study, Clin Endocrinol., 94, 242, 10.1111/cen.14334 · DOI
  7. Qi, 2018, [Hypopituitarism mode in patients with craniopharyngioma in relation to tumor growth pattern], Zhonghua yi xue za zhi., 98, 19
  8. Rostami, 2017, Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy, Acta Neurochir., 159, 2217, 10.1007/s00701-017-3311-0 · DOI
  9. Mende, 2020, Clinical situation, therapy, and follow-up of adult craniopharyngioma, J Clin Endocrinol Metab., 105, 43, 10.1210/clinem/dgz043 · DOI
  10. Wijnen, 2017, Very long-term sequelae of craniopharyngioma, Eur J Endocrinol., 176, 755, 10.1530/EJE-17-0044 · DOI
  11. Sterkenburg, 2015, Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes, Neuro Oncol., 17, 1029, 10.1093/neuonc/nov044 · DOI · Paper page
  12. Pascual, 2018, Cystic tumors of the pituitary infundibulum: seminal autopsy specimens (1899 to 1904) that allowed clinical-pathological craniopharyngioma characterization, Pituitary., 21, 393, 10.1007/s11102-018-0889-z · doi:10.1007/s11102-018-0889-z
  13. Guo, 2019, Comparative evaluation of neuroendocrine dysfunction in children with craniopharyngiomas before and after mass effects are removed, J Pediatr Endocrinol Metab., 32, 127, 10.1515/jpem-2018-0204 · doi:10.1515/jpem-2018-0204
  14. Pan, 2016, Growth patterns of craniopharyngiomas: clinical analysis of 226 patients, J Neurosurg Pediatr., 17, 418, 10.3171/2015.7.PEDS14449 · DOI
  15. Liu, 2018, Pathological relationship between adamantinomatous craniopharyngioma and adjacent structures based on QST classification, J Neuropathol Exp Neurol., 77, 1017, 10.1093/jnen/nly083 · doi:10.1093/jnen/nly083
  16. Almistehi, 2020, Secondary pituitary hormonal dysfunction patterns: tumor size and subtype matter, Pituitary., 23, 622, 10.1007/s11102-020-01067-7 · DOI
  17. Olsson, 2015, Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden, J Clin Endocrinol Metab., 100, 467, 10.1210/jc.2014-3525 · DOI · Paper page
  18. Bao, 2016, Origin of craniopharyngiomas: implications for growth pattern, clinical characteristics, and outcomes of tumor recurrence, J Neurosurg., 125, 24, 10.3171/2015.6.JNS141883 · DOI
  19. DiPatri, 2005, history of the treatment of craniopharyngiomas, ChNS., 21, 606, 10.1007/s00381-005-1224-3 · doi:10.1007/s00381-005-1224-3
  20. Hoffman, 1992, Aggressive surgical management of craniopharyngiomas in children, J Neurosurg., 76, 47, 10.3171/jns.1992.76.1.0047 · DOI · Paper page
  21. Meuric, 2005, Influence of tumor location on the presentation and evolution of craniopharyngiomas, J Neurosurg., 103, 421, 10.3171/ped.2005.103.5.0421 · DOI
  22. Prieto, 2016, Craniopharyngioma adherence: a comprehensive topographical categorization and outcome-related risk stratification model based on the methodical examination of 500 tumors, Neurosurg Focus., 41, E13, 10.3171/2016.9.FOCUS16304 · DOI
  23. Honegger, 2008, Craniopharyngioma surgery, Pituitary., 11, 361, 10.1007/s11102-008-0137-z · DOI
  24. Cheng, 2017, Effect of preserving the pituitary stalk during resection of craniopharyngioma in children on the diabetes insipidus and relapse rates and long-term outcomes, J Craniofac Surg., 28, e591, 10.1097/SCS.0000000000003920 · DOI
  25. Ocal, 2008, Permanent central diabetes insipidus with complete regression of pituitary stalk enlargement after 4 years of follow-up, J Clin Res Pediatr Endocrinol., 1, 38, 10.4008/jcrpe.v1i1.4 · doi:10.4008/jcrpe.v1i1.4
  26. Schreckinger, 2013, Post-operative diabetes insipidus after endoscopic transsphenoidal surgery, Pituitary., 16, 445, 10.1007/s11102-012-0453-1 · DOI
  27. Lopez-Serna, 2012, Treatment of craniopharyngioma in adults: systematic analysis of a 25-year experience, Arch Med Res., 43, 347, 10.1016/j.arcmed.2012.06.009 · DOI
  28. Hetelekidis, 1993, 20-year experience in childhood craniopharyngioma, Int J Radiat Oncol Biol Phys., 27, 189, 10.1016/0360-3016(93)90227-M · DOI · Paper page
  29. Chakrabarti, 2005, Long-term neurological, visual, and endocrine outcomes following transnasal resection of craniopharyngioma, J Neurosurg., 102, 650, 10.3171/jns.2005.102.4.0650 · DOI · Paper page
  30. Conti, 2019, Benefits of image-guided stereotactic hypofractionated radiation therapy as adjuvant treatment of craniopharyngiomas. A review, Childs Nerv Syst., 35, 53, 10.1007/s00381-018-3954-z · DOI
  31. Chemaitilly, 2015, Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study, J Clin Oncol., 33, 492, 10.1200/JCO.2014.56.7933 · DOI · Paper page
  32. Kawamata, 2010, Optimal treatment strategy for craniopharyngiomas based on long-term functional outcomes of recent and past treatment modalities, Neurosurg Rev., 33, 71, 10.1007/s10143-009-0220-6 · DOI
  33. Xu, 2020, Cranial irradiation alters neuroinflammation and neural proliferation in the pituitary gland and induces late-onset hormone deficiency, J Cell Mol Med., 24, 14571, 10.1111/jcmm.16086 · DOI
  34. Nie, 2017, The purine receptor P2X7R regulates the release of pro-inflammatory cytokines in human craniopharyngioma, Endocr Relat Cancer., 24, 287, 10.1530/ERC-16-0338 · DOI
  35. Zhou, 2017, Interleukin6 induces an epithelialmesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration, Mol Med Rep., 15, 4123, 10.3892/mmr.2017.6538 · DOI
  36. Neuhaus, 2017, Catecholamine metabolism induces mitochondrial DNA deletions and leads to severe adrenal degeneration during aging, Neuroendocrinology., 104, 72, 10.1159/000444680 · DOI
  37. Mao, 2019, Interleukin-1alpha leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis, Metabolism., 101, 153998, 10.1016/j.metabol.2019.153998 · DOI
  38. Cook, 2009, American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients-−2009 update, Endocr Pract., 2009, 1, 10.4158/EP.15.S2.1 · DOI · Paper page
  39. Fenske, 2012, Clinical review: current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review, J Clin Endocrinol Metab., 97, 3426, 10.1210/jc.2012-1981 · DOI · Paper page
  40. Qi, 2013, Growth and weight of children with craniopharyngiomas based on the tumour location and growth pattern, J Clin Neurosci., 20, 1702, 10.1016/j.jocn.2012.12.030 · DOI
  41. Tan, 2017, The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres, Eur J Endocrinol., 176, 359, 10.1530/EJE-16-0812 · DOI
  42. Sun, 2017, Factors related to endocrine changes and hormone substitution treatment during pre- and post-operation stages in craniopharyngioma, Oncol Lett., 13, 250, 10.3892/ol.2016.5418 · doi:10.3892/ol.2016.5418
  43. Boekhoff, 2019, Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007, Pituitary., 22, 532, 10.1007/s11102-019-00983-7 · DOI
  44. Siebert, 2018, The use and abuse of human growth hormone in sports, Sports Health., 10, 419, 10.1177/1941738118782688 · DOI
  45. Losa, 2020, Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence, J Clin Endocrinol Metab, 105, dgaa089, 10.1210/clinem/dgaa089 · DOI
  46. Tiulpakov, 1998, Growth in children with craniopharyngioma following surgery, Clin Endocrinol., 49, 733, 10.1046/j.1365-2265.1998.00590.x · DOI
  47. Xu, 2017, features of growth hormone deficiency in children with short stature caused by pituitary lesions, Exp Ther Med., 13, 3474, 10.3892/etm.2017.4377 · DOI
  48. Alotaibi, 2018, Physiologic growth hormone-replacement therapy and craniopharyngioma recurrence in pediatric patients: a meta-analysis, World Neurosurg., 109, 487, 10.1016/j.wneu.2017.09.164 · DOI
  49. Smith, 2016, Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study, J Neurosurg Pediatr., 18, 408, 10.3171/2016.4.PEDS16112 · DOI
  50. Boekhoff, 2018, Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the german craniopharyngioma registry (HIT-Endo), Eur J Endocrinol., 179, 331, 10.1530/EJE-18-0505 · DOI · Paper page
  51. Monson, 2003, Long-term experience with GH replacement therapy: efficacy and safety, Eur J Endocrinol, 2003, S9, 10.1530/eje.0.148s009 · DOI
  52. Yuen, 2018, Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on growth hormone replacement, J Clin Endocrinol Metab., 103, 768, 10.1210/jc.2017-01542 · DOI
  53. Ogawa, 2015, Prognostic factors of craniopharyngioma with special reference to autocrine/paracrine signaling: underestimated implication of growth hormone receptor, Acta Neurochir., 157, 1731, 10.1007/s00701-015-2519-0 · DOI
  54. Matovic, 2019, Adrenocorticotropic hormone (ACTH) and cortisol monitoring as stress markers during laparoscopic cholecystectomy: standard and low intraabdominal pressure and open cholecystectomy, Med Arch., 73, 257, 10.5455/medarh.2019.73.257-261 · DOI
  55. Rose, 2005, ACTH deficiency in childhood cancer survivors, Pediatr Blood Cancer., 45, 808, 10.1002/pbc.20327 · DOI
  56. Thompson, 2019, Management of hypothalamic disease in patients with craniopharyngioma, Clin Endocrinol (Oxf)., 90, 506, 10.1111/cen.13929 · DOI
  57. Garrè, 2007, Craniopharyngioma: modern concepts in pathogenesis and treatment, Curr Opin Pediatr., 19, 471, 10.1097/MOP.0b013e3282495a22 · DOI · Paper page
  58. Sherlock, 2009, ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly, J Clin Endocrinol Metab., 94, 4216, 10.1210/jc.2009-1097 · DOI · Paper page
  59. Okinaga, 2005, High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions, Endocr J., 52, 751, 10.1507/endocrj.52.751 · DOI
  60. Alvarez, 2006, Craniopharyngiomas, J Neurosci Nurs., 38, 362, 10.1097/01376517-200610000-00007 · doi:10.1097/01376517-200610000-00007
  61. Pereira, 2005, High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma, Clin Endocrinol., 62, 197, 10.1111/j.1365-2265.2004.02196.x · DOI · Paper page
  62. Tomlinson, 2001, Association between premature mortality and hypopituitarism, Lancet., 357, 425, 10.1016/S0140-6736(00)04006-X · DOI · Paper page
  63. Emmert, 2021, Case report of transgender patient with gonadotropic dysfunction secondary to craniopharyngioma: toward improving understanding of biopsychosocial dynamics of gender identity in neurosurgical care, World Neurosurg., 145, 448, 10.1016/j.wneu.2020.09.168 · DOI
  64. Holmer, 2011, Hypothalamic involvement and insufficient sex steroid supplementation are associated with low bone mineral density in women with childhood onset craniopharyngioma, Eur J Endocrinol., 165, 25, 10.1530/EJE-11-0229 · DOI
  65. Du, 2014, Hypopituitarism and successful pregnancy, Int J Clin Exp Med., 7, 4660
  66. Sowithayasakul, 2021, Pregnancies after childhood craniopharyngioma: results of Kraniopharyngeom 2000/2007 and review of the literature, Neuroendocrinology., 111, 16, 10.1159/000506639 · DOI
  67. Halac, 2005, Endocrine manifestations of craniopharyngioma, Childs Nerv Syst., 21, 640, 10.1007/s00381-005-1246-x · DOI
  68. Aversa, 2016, Key-role of thyrotropin deficiency in disclosing craniopharyngioma diagnosis in a short girl with Hashimoto's thyroiditis, Minerva Pediatr., 68, 152
  69. Cook, 2016, Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma, J Pediatr Endocrinol Metab., 29, 995, 10.1515/jpem-2015-0445 · DOI
  70. Romano, 2015, from autism to eating disorders and more: the role of oxytocin in neuropsychiatric disorders, Front Neurosci., 9, 497, 10.3389/fnins.2015.00497 · DOI
  71. Marazziti, 2008, Catena Dell'osso M. The role of oxytocin in neuropsychiatric disorders, Curr Med Chem., 15, 698, 10.2174/092986708783885291 · DOI
  72. Daughters, 2017, Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability, Endocrine., 57, 166, 10.1007/s12020-017-1332-3 · DOI
  73. Gebert, 2018, De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function, Psychoneuroendocrinology., 88, 61, 10.1016/j.psyneuen.2017.11.006 · DOI
  74. Daubenbuchel, 2019, Eating behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of hypothalamic involvement, Pediatr Obes., 14, e12527, 10.1111/ijpo.12527 · DOI · Paper page
  75. Daubenbuchel, 2016, Oxytocin in survivors of childhood-onset craniopharyngioma, Endocrine., 54, 524, 10.1007/s12020-016-1084-5 · DOI · Paper page
  76. Thompson, 1986, The osmotic thresholds for thirst and vasopressin release are similar in healthy man, Clin Sci, 71, 651, 10.1042/cs0710651 · DOI · Paper page
  77. Harrois, 2019, Diabetes insipidus and syndrome of inappropriate antidiuretic hormone in critically ill patients, Crit Care Clin., 35, 187, 10.1016/j.ccc.2018.11.001 · DOI
  78. Pratheesh, 2013, Incidence, predictors and early post-operative course of diabetes insipidus in paediatric craniopharygioma: a comparison with adults, Childs Nerv Syst., 29, 941, 10.1007/s00381-013-2041-8 · DOI
  79. Lindner, 2013, Hypernatremia in critically ill patients, J Critic Care, 28, 216.e11, 10.1016/j.jcrc.2012.05.001 · DOI · Paper page
  80. Xiong, 2016, [Influence of preventive use of vasopressin tannate on diabetes insipidus and serum sodium at the early postoperation of craniopharyngioma], J Central South Univ Med Sci., 41, 1058, 10.11817/j.issn.1672-7347.2016.10.008 · doi:10.11817/j.issn.1672-7347.2016.10.008
  81. Karavitaki, 2014, Management of craniopharyngiomas, J Endocrinol Invest., 37, 219, 10.1007/s40618-013-0050-9 · DOI
  82. Venegas, 2015, en representacion del area de conocimiento de Neuroendocrinologia de la S. (Practice guideline for diagnosis and treatment of craniopharyngioma and parasellar tumors of the pituitary gland), Endocrinol Nutr, 62, e1, 10.1016/j.endonu.2014.05.005 · DOI
  83. Winkfield, 2011, Long-term clinical outcomes following treatment of childhood craniopharyngioma, Pediatr Blood Cancer., 56, 1120, 10.1002/pbc.22884 · doi:10.1002/pbc.22884
  84. Loh, 2008, Disorders of water and salt metabolism associated with pituitary disease, Endocrinol Metab Clin North Am, 37, 213, 10.1016/j.ecl.2007.10.008 · DOI
  85. Cote, 2020, Optimizing pre-, intra-, and postoperative management of patients with sellar pathology undergoing transsphenoidal surgery, Neurosurg Focus., 48, E2, 10.3171/2020.3.FOCUS2043 · DOI
  86. Seay, 2020, Diagnosis and management of disorders of body tonicity-hyponatremia and hypernatremia: core curriculum 2020, Am J Kidney Dis., 75, 272, 10.1053/j.ajkd.2019.07.014 · doi:10.1053/j.ajkd.2019.07.014
  87. Refardt, 2020, Diabetes insipidus: an update, Endocrinol Metab Clin North Am., 49, 517, 10.1016/j.ecl.2020.05.012 · DOI
  88. Mutter, 2021, Diabetes insipidus: pathogenesis, diagnosis, and clinical management, Cureus., 13, e13523, 10.7759/cureus.13523 · DOI
  89. Vance, 2004, Treatment of patients with a pituitary adenoma: one clinician's experience, Neurosurg Focus., 16, E1, 10.3171/foc.2004.16.4.2 · doi:10.3171/foc.2004.16.4.2
  90. Hensen, 1999, Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas, Clin Endocrinol., 50, 431, 10.1046/j.1365-2265.1999.00666.x · DOI · Paper page
  91. Dumont, 2005, Postoperative care following pituitary surgery, J Intensive Care Med., 20, 127, 10.1177/0885066605275247 · DOI
  92. Oksnes, 2015, Optimal glucocorticoid replacement in adrenal insufficiency, Best Pract Res Clin Endocrinol Metab., 29, 3, 10.1016/j.beem.2014.09.009 · DOI
  93. Falorni, 2013, Therapy of adrenal insufficiency: an update, Endocrine., 43, 514, 10.1007/s12020-012-9835-4 · DOI
  94. Zeni, 2019, Evaluation of treatment of central hypothyroidism versus primary hypothyroidism in relation to levothyroxine replacement dose, Endocr Pract., 25, 663, 10.4158/EP-2018-0533 · DOI
  95. Parretti, 2016, Current recommendations in the management of hypothyroidism: developed from a statement by the British Thyroid Association Executive, Br J Gen Pract., 66, 538, 10.3399/bjgp16X687493 · DOI
  96. Aimaretti, 2015, Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA, J Endocrinol Invest., 38, 377, 10.1007/s40618-014-0201-7 · DOI · Paper page
  97. Losa, 2008, Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency, Thyroid., 18, 1249, 10.1089/thy.2008.0266 · DOI · Paper page
  98. Yao, 2021, The effects of recombinant human growth hormone therapy on thyroid function in pediatric patients with growth hormone deficiency, Transl Pediatr., 10, 851, 10.21037/tp-20-401 · DOI
  99. Çakir, 2015, Retrospective evaluation of pubertal development and linear growth of girls with Turner Syndrome treated with oral and transdermal estrogen, J Pediatr Endocrinol Metab., 28, 1219, 10.1515/jpem-2014-0007 · DOI
  100. Backeljauw, 2019, Sex hormone replacement therapy for individuals with Turner syndrome, Am J Med Genet C Semin Med Genet., 181, 13, 10.1002/ajmg.c.31685 · DOI
  101. Ascoli, 2006, Hypopituitarism, Pituitary., 9, 335, 10.1007/s11102-006-0416-5 · DOI
  102. Conway, 2000, Premature ovarian failure, Br Med Bull., 56, 643, 10.1258/0007142001903445 · DOI
  103. Alexandraki, 2019, Management of hypopituitarism, J Clin Med, 8, 2153, 10.3390/jcm8122153 · DOI
  104. Levy, 2019, Diabetes insipidus, BMJ., 364, l321, 10.1136/bmj.l321 · DOI
  105. Woodmansee, 2015, American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Postoperative Management Following Pituitary Surgery, Endocr Pract., 21, 832, 10.4158/EP14541.DSCR · DOI
  106. Sadashivam, 2020, Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome, Clin Neurol Neurosurg., 192, 105711, 10.1016/j.clineuro.2020.105711 · DOI
  107. Gump, 2015, Identification of targets for rational pharmacological therapy in childhood craniopharyngioma, Acta Neuropathol Commun., 3, 30, 10.1186/s40478-015-0211-5 · DOI
  108. Brastianos, 2014, Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas, Nat Genet., 46, 161, 10.1038/ng.2868 · DOI · Paper page
  109. Ascierto, 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma, J Clin Oncol., 31, 3205, 10.1200/JCO.2013.49.8691 · DOI · Paper page
  110. Hengartner, 2020, Adamantinomatous craniopharyngioma: moving toward targeted therapies, Neurosurg Focus., 48, E7, 10.3171/2019.10.FOCUS19705 · DOI
  111. Brastianos, 2016, Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy, J Natl Cancer Inst., 108, djv310, 10.1093/jnci/djv310 · DOI · Paper page
  112. Grob, 2019, Targeting IL-6 Is a potential treatment for primary cystic craniopharyngioma, Front Oncol., 9, 791, 10.3389/fonc.2019.00791 · DOI

Cited by

See all 48

Metadata

Authors
Zhou, Z., Zhang, S., & Hu, F.
Venue
Frontiers in Neurology
Published
2021-12-02
Volume
12
ISSN
1664-2295
Cited by
48
References
23

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endocrine Disorder in Patients With Craniopharyngioma. https://app.cochat.ai/papers/10.3389/fneur.2021.737743
The paper
Zhou, Z., Zhang, S., & Hu, F. (2021). Endocrine Disorder in Patients With Craniopharyngioma. Frontiers in Neurology. https://doi.org/10.3389/fneur.2021.737743

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.